# Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

> **NCT04833101** · PHASE4 · COMPLETED · sponsor: **Jiangsu Province Centers for Disease Control and Prevention** · enrollment: 120 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** recombinant Ad5 vectored COVID-19 vaccine
- **BIOLOGICAL:** RBD-based protein subunit vaccine (ZF2001) against COVID-19
- **BIOLOGICAL:** trivalent split influenza vaccine

## Key facts

- **NCT ID:** NCT04833101
- **Lead sponsor:** Jiangsu Province Centers for Disease Control and Prevention
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-07
- **Primary completion:** 2021-09-18
- **Final completion:** 2022-03-04
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04833101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04833101, "Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04833101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*